bevacizumab + PD-1 monoclonal antibody (Jiangsu Provincial People's Hospital)

Bevacizumab + PD-1 monoclonal antibody is an investigational combination therapy being evaluated by The First Affiliated Hospital with Nanjing Medical University. This regimen is specifically being studied as a preoperative neoadjuvant therapy for patients with microsatellite stable (MSS) colorectal cancer that has metastasized to the liver. Bevacizumab is a humanized monoclonal antibody that inhibits vascular endothelial growth factor (VEGF), thereby blocking tumor angiogenesis. The PD-1 monoclonal antibody component (the specific agent is not identified in the trial record) is a checkpoint inhibitor that prevents the interaction between PD-1 on T-cells and its ligands on tumor cells, enhancing the immune system's ability to recognize and destroy cancer cells. The combination is intended to convert unresectable liver metastases to resectable ones and improve the pathological complete response rate in the MSS population, which is typically resistant to immunotherapy alone.

Other names

Bevacizumab Combined With PD-1 Monoclonal AntibodyBevacizumab + PD-1 mAb